Annals of Emergency Medicine
Volume 36, Issue 3 , Page 254 , September 2000

In response

References 

  1. Hacke W, Kaste M, Fieschi C, et al.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASSII). Lancet. 1998;352:1245–1251
  2. Hacke W, Kaste M, Fieschi C, et al.  Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke—The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017–1025
  3. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Study Group. N Engl J Med. 1995;333:1581–1587
  4. Lyden PD, Lau GT. A critical appraisal of stroke evaluation and rating scales. Stroke. 1991;22:1345–1352
  5. Lyden P, Brott T, Tilley B, et al.  Improved reliability of the NIH Stroke Scale using video training. Stroke. 1994;25:2220–2226
  6. Goldstein LB, Bertels C, Davis JN. Interrater reliability of the NIH Stroke Scale. Arch Neurol. 1990;46:660–662
  7. Williams LS, Weinberger M, Harris LE, et al.  Measuring quality of life in a way that is meaningful to stroke patients. Neurology. 1999;53:1839–1843
  8. Broe GA, Jorm AF, Creasey H, et al.  Impact of chronic systemic and neurological disorders on disability, depression and life satisfaction. Int J Geriatr Psychiatry. 1998;13:667–673
  9. Carod-Artal FJ. Measurement of the quality of life in stroke survivors. Rev Neurol. 1999;29:447–456
  10. Hallan S, Asberg A, Indredavik B, et al.  Quality of life after cerebrovascular stroke: a systematic study of patients’ preferences for different functional outcomes. J Intern Med. 1999;246:309–316

PII: S0196-0644(00)70178-8

Annals of Emergency Medicine
Volume 36, Issue 3 , Page 254 , September 2000

Article Tools